TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34958142
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day montelukast (Group 3)
Study: 34958142
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Group 1)
Study: 35131378
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care (medication therapy management and telephonic follow‐up with visits to family physicians, nurses, and dietitians)
Study: 34656226
Drug: Liposomal irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal irinotecan (70 mg/m2 for 90 min) plus leucovorin (400 mg/m2 for 30 min) and fluorouracil (2400 mg/m2 for 46 h) every 2 weeks
Study: 36282079
Drug: CSL112 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 (2 g and 6 g)
Study: 35268057
Drug: Ca+vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca+vitamin D supplements (S)
Study: 35268057
Drug: Control/placebo pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control/placebo pills (C)
Study: 34458731
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (management of antimicrobial therapy by the treating team)
Study: 36708956
Drug: Vortioxetine 20
Normalized name: vortioxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 20 mg/day
Study: 33454989
Drug: Thyroxine (T4)
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thyroxine (T4) and Thyroid-stimulating hormone (TSH)
Study: 33454989
Drug: Thyroid hormones
Normalized name: Thyroid hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormones (fT4 and TSH)
Study: 33712267
Drug: Second-line therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line therapy with Gem/NabP or FOLFIRINOX
Study: 35311753
Drug: Closed-incision negative-pressure
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-incision negative-pressure wound therapy for 5 days
Study: 35311753
Drug: Closed-incision negative-pressure
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-incision negative-pressure wound therapy
Study: 32047245
Drug: 5 g TestimTM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g TestimTM gel (containing 50 mg testosterone)
Study: 32892305
Drug: Preferred music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferred music therapy (PMT) which included educational counseling (EC) plus 15, 30-min preferred music sessions (PMS)
Study: 32725584
Drug: Mirabegron 25
Normalized name: mirabegron 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 25 mg/day
Study: 36069798
Drug: Blended Cognitive
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended Cognitive Behavioral Therapy (B‐CBT) - 6 sessions of face-to-face CBT alternated with 6-8 web-based CBT self-help modules.
Study: 36069798
Drug: Face-to-Face Cognitive
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-Face Cognitive Behavioral Therapy (FtF‐CBT) - 12 sessions of traditional face-to-face CBT.
Study: 36069798
Drug: Blended Cognitive
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended Cognitive Behavioral Therapy (B‐CBT)
Study: 34111592
Drug: Uva ursi
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uva ursi (UU) 105 mg 3 × 2 tablets for 5 days
Study: 34111592
Drug: Fosfomycin 3-g
Normalized name: fosfomycin
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin 3-g single dose
Study: 35567836
Drug: All dosing
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosing regimens
Study: 33221606
Drug: Interpersonal Psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal Psychotherapy (IPT) group treatment for perinatal depression, 12 sessions
Study: 32328709
Drug: Drospirenone-only pill
Normalized name: drospirenone Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone-only pill 4 mg
Study: 32328709
Drug: Desogestrel 0.075
Normalized name: desogestrel 0.075 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel 0.075 mg
Study: 35210118
Drug: Intradermal fractional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal fractional third dose of AZD1222 vaccine (20% of standard dose)
Study: 35210118
Drug: Intradermal fractional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal fractional third dose of AZD1222 vaccine (40% of standard dose)
Study: 35210118
Drug: Standard intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intramuscular third dose of AZD1222 vaccine
Study: 34735395
Drug: 35% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% N2O with i.v. remifentanil infusion at 0.1 μg kg‐1 min‐1
Study: 34735395
Drug: 50% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% N2O with i.v. remifentanil infusion at 0.1 μg kg‐1 min‐1 (gas active control)
Study: 34735395
Drug: i.v. remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. remifentanil infusion at 0.1 μg kg‐1 min‐1
Study: 33788484
Drug: Acupoint electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acupoint electrical stimulation therapy at Huantiao (GB 30), Futu (ST 32), Zusanli (ST 36), Xuanzhong (GB 39), and Taichong (LR 3), 2 times daily for 7 days.
Study: 33788484
Drug: Routine basic
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine basic treatment (Control group).
Study: 33788484
Drug: Acupoint electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acupoint electrical stimulation therapy.
Study: 34534292
Drug: TS‐161 (15-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS‐161 (15-400 mg single dose)
Study: 34534292
Drug: TS‐161 (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS‐161 (50-150 mg multiple doses over 10 days)
Study: 34534292
Drug: TS‐161 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS‐161 (100 mg single dose)
Study: 32771034
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa oil (MARNYS® Cuminmar) 500 mg softgel capsules, one capsule orally twice daily for 10 days plus standard of care treatment (antipyretic, antitussive)
Study: 38879506
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment
Study: 33635779
Drug: Choice of
Normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [MediChoice of Hydrogen Peroxide 3 10 Volume]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice of medication reminder modality (text, email, phone)
Study: 35452419
Drug: Bevacizumab (BVZ)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BVZ) plus XELOX chemotherapy with mindfulness-based stress reduction (MBSR) intervention
Study: 35452419
Drug: XELOX chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XELOX chemotherapy with conventional care
Study: 34739648
Drug: Remote Ischaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote Ischaemic Conditioning (RIC) - four 5-min cycles of inflation (20 mmHg above systolic blood pressure) and deflation of an automated blood pressure cuff placed on the upper arm, applied daily for 2 days.
Study: 34739648
Drug: Sham control
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham control - similar protocol but with low-pressure inflation of 20 mmHg and deflation, applied daily for 2 days.
Study: 33955942
Drug: Yogic pranayama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogic pranayama and diaphragmatic breathing exercises (daily for 6 months)
Study: 32943015
Drug: Three-monthly multimodal
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-monthly multimodal vascular risk factor intervention jointly delivered by the trial team and General Practitioner (GP)
Study: 39118020
Drug: Mandibular implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular implant overdentures
Study: 33893865
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment with meibomian gland expression (MGX)
Study: 33893865
Drug: MGX-alone treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGX-alone treatment
Study: 33893865
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment with MGX
Study: 35084893
Drug: Family-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused therapy (FFT) for 4 months
Study: 34530894
Drug: Group-based Problem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based Problem Management Plus (group PM+) with antidepressant therapy (ADT)
Study: 35690556
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Care Treatment (SCT)
Study: 34396571
Drug: 900 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 µg εPA‐44
Study: 34396571
Drug: 600 µg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 µg εPA‐44
Study: 34653953
Drug: 0.02% HOCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% HOCl nasal spray three times a day for two months
Study: 33403697
Drug: Intradermal adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intradermal adalimumab (40 mg, 0.4 mL)
Study: 33403697
Drug: Subcutaneous adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous adalimumab (40 mg)
Study: 34621450
Drug: Home Medication
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home Medication Review by Community Pharmacists (HMR‐CP)
Study: 35091050
Drug: Quetiapine (400-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (400-600 mg)
Study: 35091050
Drug: Lithium (1.0-1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (1.0-1.2 mEq/L)
Study: 35719216
Drug: Topical lidocaine-prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine-prilocaine (EMLA®)
Study: 35373776
Drug: Web-based psychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based psychosocial therapy program via smartphone for 6 weeks
Study: 33950184
Drug: Home-delivered pill
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home-delivered pill packs in prepackaged blisters
Study: 33950184
Drug: Routine pharmacy
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Routine pharmacy prescriptions (Control)
Study: 32840201
Drug: Silver-impregnated ceramic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver-impregnated ceramic tablet
Study: 35717048
Drug: Risk-adapted intraoperative
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-adapted intraoperative radiation therapy (IORT)
Study: 35717048
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiation therapy (control)
Study: 32348638
Drug: Inhaled steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroids (IS) before weaning
Study: 32348638
Drug: Inhaled steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroids (IS) after weaning
Study: 32348638
Drug: No inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: No inhaled steroids (IS)
Study: 34910554
Drug: Genomically directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genomically directed therapy (arm A)
Study: 34910554
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of physician choice (TPC) (arm B)
Study: 32060099
Drug: High-dose icotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose icotinib (250 mg, thrice daily; L858R-HD)
Study: 32060099
Drug: Routine-dose icotinib
Normalized name: nicotine Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine-dose icotinib (125 mg, thrice daily; L858R-RD)
Study: 32060099
Drug: Routine-dose icotinib
Normalized name: nicotine Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine-dose icotinib (125 mg, thrice daily; 19-Del-RD)
Study: 32060099
Drug: High-dose icotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose icotinib (L858R-HD)
Study: 32060099
Drug: Routine-dose icotinib
Normalized name: nicotine Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine-dose icotinib (L858R-RD)
Study: 32060099
Drug: Routine-dose icotinib
Normalized name: nicotine Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine-dose icotinib (19-Del-RD)
Study: 36322937
Drug: Low-dose hydroxyurea
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydroxyurea (10 mg/kg per day)
Study: 36322937
Drug: Moderate-dose hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose hydroxyurea (20 mg/kg per day)
Study: 32892320
Drug: Spirulina (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina (6 g/day for 7 days)
Study: 32745555
Drug: Retreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retreatment with immunosuppressive therapy
Study: 33471029
Drug: Systematic echocardiographic
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic echocardiographic screening followed by secondary antibiotic prophylaxis
Study: 32213659
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (TRT) - Testosterone undecanoate injection three times/6 months (n = 20)
Study: 34653515
Drug: Peanut Epicutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut Epicutaneous Immunotherapy (49 participants)
Study: 34653515
Drug: Egg Oral
Normalized name: Egg Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg Oral Immunotherapy or Baked Egg Diet (92 participants)
Study: 34464306
Drug: levobupivacaine 0.5
Normalized name: levobupivacaine 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine 0.5 mg/kg plus 1?g/kg dexmedetomidine and 0.9% isotonic (Group 4)
Study: 34464306
Drug: levobupivacaine 0.5
Normalized name: levobupivacaine 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine 0.5 mg/kg plus 0.9% isotonic (Group 2)
Study: 34464306
Drug: 1?g/kg dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1?g/kg dexmedetomidine plus 0.9% isotonic (Group 3)
Study: 34464306
Drug: 0.9% isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% isotonic 20 ml (Group 1)
Study: 34893026
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with patient-controlled intravenous analgesia (PCIA)
Study: 33808849
Drug: Traditional Thai
Normalized name: Thai galangal extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Thai Massage (TTM) - six weekly 1‐h sessions
Study: 32458080
Drug: Combined 308-nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 308-nm excimer lamp and topical mometasone furoate cream
Study: 32458080
Drug: 308-nm excimer
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm excimer lamp alone (monotherapy)
Study: 36454561
Drug: BRIGHT (tele-cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRIGHT (tele-cognitive behavioral therapy)
Study: 32271671
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone (E)
Study: 35416182
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g each fish and soybean oil daily for 6 weeks
Study: 32739509
Drug: Sulodexide (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide (oral dose twice a day for 7 days before sclerotherapy, continued for 3 months)
Study: 32739509
Drug: Standard sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sclerotherapy protocol (Polidocanol as sclerosing agent, 20 to 30 mm Hg compression stockings for 7 days)
Study: 39696609
Drug: Oral PrEP
Normalized name: Iron bivalent, oral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PrEP
Study: 32478030
Drug: Video treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video treatment group (watching a 5-min video about the possible health hazards of MP use)
Study: 36064731
Drug: Immediate group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate group with access to the wristband solution and standard care
Study: 32960242
Drug: Prophylactic negative
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic negative pressure wound therapy (n = 816, median duration 4 days)
Study: 35677636
Drug: Compound lactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound lactic acid bacteria capsules combined with escitalopram
Study: 35465007
Drug: Dexmedetomidine (0.2‐0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.2‐0.7 μg/kg/h)
Study: 32532601
Drug: Individualized homoeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized homoeopathic treatment (11 medicines prescribed in potencies from 6C to 1M)
Study: 34687634
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg daily for 12 months
Study: 33301009
Drug: 3.3 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.3 mL/kg of concentrated beetroot juice containing 200 µmol/kg of nitrate
Study: 33301009
Drug: 3.3 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.3 mL/kg of concentrated beetroot juice containing 400 µmol/kg of nitrate
Study: 33301009
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of nitrate
Study: 35643988
Drug: Three treatments
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three treatments with CPM‐HA20G (total 3 ml per side)
Study: 35643988
Drug: One treatment
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One treatment with CPM‐HA20G (total 1.5 ml per side)
Study: 33745609
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (500 mg daily for 8 weeks)
Study: 33044240
Drug: Antifungal drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal drugs in high-risk critically ill patients without microbiologic documentation of Candida infection
Study: 33044240
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of echinocandins for treating invasive candidiasis
Study: 33044240
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of fungal biomarkers for early initiation or interruption of antifungal therapy
Study: 34560265
Drug: SaMBA-COPD intervention
Normalized name: Jasminum sambac flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SaMBA-COPD intervention with lay health coaches, including referral to a pharmacist for antibiotic and oral steroid rescue packs and support for a structured home exercise routine.
Study: 33637618
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of conbercept (0.25 mg)
Study: 33637618
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of ranibizumab (0.25 mg)
Study: 34540595
Drug: Internet-based self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based self-help intervention (8 modules based on cognitive behavioral therapy)
Study: 33361317
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g/day)
Study: 35758093
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day aspirin (ASA)
Study: 32345787
Drug: Vaginal CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal CO2 laser treatment
Study: 33970455
Drug: Centhaquine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centhaquine (0.01 mg/kg in 100 ml normal saline infusion over 1 h)
Study: 33970455
Drug: Control (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (100 ml normal saline infusion over 1 h)
Study: 33931900
Drug: Gliadin-protected SOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliadin-protected SOD (GP-SOD; 1 g/day for 12 weeks followed by 0.5 g/day for 12 weeks) + NB-UVB
Study: 32065006
Drug: THC:CBD oromucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC:CBD oromucosal spray (nabiximols)
Study: 35723751
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide + 2% chlorhexidine-gel (Ca(OH)2 + 2% CHX-gel)
Study: 35723751
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide + saline solution (Ca(OH)2 + SSL)
Study: 35395555
Drug: Soy nut
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy nut consumption (67 g/day providing 25.5 g protein and 174 mg isoflavones)
Study: 35395555
Drug: Soy nut
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy nut consumption (67 g/day)
Study: 34517775
Drug: Polypharmacy (taking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (taking ?5 medications)
Study: 34517775
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between number of medications and number of PIMs
Study: 34517775
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between number of medications and anticholinergic score
Study: 34268888
Drug: Large volume
Normalized name: NEBULIZER,LARGE VOLUME #1770
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large volume subcutaneous injection (1, 8, and 20 cP viscosities, up to 10ml in abdomen and 5ml in thigh)